Naga P. Chalasani, MD
David W. Crabb Professor of Gastroenterology and Hepatology
Professor of Medicine
Adjunct Professor of Anatomy, Cell Biology & Physiology
- Address
-
702 Rotary Circle, Suite 225
Indianapolis, IN 46202 - PubMed:
-
Bio
Dr. Chalasani completed medical school in India before moving to the United States to pursue an Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution.
He joined Indiana University School of Medicine in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani currently serves as the David W. Crabb Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology & Physiology, and Director of the Terance Kahn Liver Research Program.
Throughout his career, he has held numerous leadership positions, including Chief of the Division of Gastroenterology and Hepatology (2007–2020), Associate Dean for Clinical Research (2017–2020), Interim Chair of the Department of Medicine (2020–2021), and Vice President for Academic Affairs at Indiana University Health (2022–2024).
Dr. Chalasani is a highly regarded clinician who has been recognized as a Top Doctor for more than 15 consecutive years. He has maintained continuous National Institutes of Health (NIH) funding since 1999 and currently serves as Principal Investigator on multiple NIH-funded U01 and R01 awards.
Internationally recognized for his contributions to the fields of metabolic dysfunction-associated steatotic liver disease (MASLD) and drug-induced liver injury (DILI), Dr. Chalasani is among the most published and cited investigators at Indiana University. As of September 2026, his Google Scholar profile reflected an H-index of 130 and more than 87,000 citations. In 2026, he was named Co-Editor-in-Chief of HEPATOLOGY, the flagship journal of the American Association for the Study of Liver Diseases (AASLD), further recognizing his leadership and impact in the field of hepatology.
He is an elected member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP), and the National Academy of Medical Sciences–India (2024). In addition to his research accomplishments, he has mentored more than 75 undergraduate and graduate students, medical students, subspecialty trainees, and junior faculty members. Twenty of his mentees have gone on to secure federal funding, including K awards, U01, R21, and R01 grants, Department of Defense funding, and VA Merit Review awards.
In recognition of his extraordinary contributions to hepatology research and mentorship, the Naga P. Chalasani Endowed Professorship in Gastroenterology and Hepatology was established at Indiana University School of Medicine in October 2022.
Key Publications
- Siddiqui MS, Van Natta ML, Connelly MA, Clark J, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Loomba R, Chalasani N, Kowdley KV, Hameed B, Wilson LA, Yates KP, Belt P, Kleiner DE, Behling C, Tonascia J, Sanyal AJ. The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease. Nat Commun. 2026 Jun 23;17(1):5362. doi: 10.1038/s41467-026-73742-5. PMID: 42337268; PMCID: PMC13291223.
- Yoder L, Tapper EB, Kalman R, Rinella M, Bendin N, Verma M, Pike F, Chalasani N, Nalumasu N, Orman ES. The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial. Hepatol Commun. 2026 Jun 19;10(7):e0990. doi: 10.1097/HC9.0000000000000990. PMID: 42319136; PMCID: PMC13286549.
- Miller K, Wilson LA, Vilar-Gomez E, Samala N, Yuan L, Ajmera V, Kleiner DE, Chalasani N. Histologic severity is identical between normal weight and overweight adults with MASLD: Implications for the definition of lean MASLD. Hepatol Commun. 2026 Jun 12;10(7):e0969. doi: 10.1097/HC9.0000000000000969. PMID: 42275579; PMCID: PMC13263071.
- Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ; SYNCHRONIZE-MASLD Investigators. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026 Aug;32(8):2948-2958. doi: 10.1038/s41591-026-04479-3. Epub 2026 Jun 7. Erratum in: Nat Med. 2026 Aug 25. doi: 10.1038/s41591-026-04650-w. PMID: 42252333; PMCID: PMC13472939.
- Dasarathy S, Tu W, Welch N, Gawrieh S, Yu Y, Tang Q, Kettler C, Sanyal AJ, Szabo G, Shah VH, Bataller R, Nagy LE, McClain CJ, Chalasani N, Kerr T, Mitchell MC; for AlcHepNet Investigators. Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study. Hepatology. 2026 Jun 1;83(6):1469-1482. doi: 10.1097/HEP.0000000000001513. Epub 2025 Sep 9. PMID: 40924794; PMCID: PMC12672022.
- Chalasani N, Tillman EJ, Billes SK, Rolph T, Noureddin M. Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH. Hepatology. 2026 Aug 1;84(2):617-620. doi: 10.1097/HEP.0000000000001792. Epub 2026 May 12. PMID: 42127430; PMCID: PMC13374643.
- Chalasani N, Vuppalanchi R, Noureddin M, Shiffman ML, Lawitz E, Mena E, Gunn NT, Ladron de Guevara L, Elgouhari H, Safadi R, Jamil K, Harrison SA, Alkhouri N. Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial. Hepatology. 2026 May 1. doi: 10.1097/HEP.0000000000001774. Epub ahead of print. PMID: 42065864.
- Nephew LD, Cotter T, Singal A, Arab JP, Behari J, Tang Q, Gawrieh S, Tu W, Chalasani N. Neighborhood Disadvantage and Access to Liver Transplant Referral for Severe Alcohol-Associated Hepatitis. JAMA Netw Open. 2026 Mar 2;9(3):e262567. doi: 10.1001/jamanetworkopen.2026.2567. PMID: 41854611; PMCID: PMC13003376.
- Schwantes-An TH, Abreu MA, Neuschwander-Tetri BA, Wang J, Guo X, Tan J, Hegele RA, Davidson NO, Lotta L, Verweij N, Yates KP, Rotter JI, Chalasani N. Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD. Liver Int. 2026 Feb;46(2):e70486. doi: 10.1111/liv.70486. PMID: 41514510; PMCID: PMC12789714.
- De A, Chalasani N, Duseja A. Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterol Clin North Am. 2026 Mar;55(1):185-202. doi: 10.1016/j.gtc.2025.09.003. Epub 2025 Nov 7. PMID: 41581949.
- Vilar-Gomez E, Yates KP, Kleiner DE, Behling C, Cummings OW, Wilson LA, Liang T, Jarasvaraparn C, Loomba R, Schwimmer JB, Sanyal AJ, Hoofnagle J, Chalasani N. Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. 2026 Mar;84(3):502-516. doi: 10.1016/j.jhep.2025.09.013. Epub 2025 Sep 24. PMID: 40998180; PMCID: PMC12495455.
- Vilar-Gomez E, Nephew L, Gawrieh S, Vuppalanchi R, Kettler C, Pike F, Tu W, Samala N, Liangpunsakul S, Chalasani N. Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States. J Hepatol. 2026 Jan;84(1):18-34. doi: 10.1016/j.jhep.2025.06.033. Epub 2025 Aug 27. PMID: 40866123.
- Gawrieh S, Yao J, Guo X, Diehl AM, Rotter JI, Chalasani NP. Biological Age, PNPLA3, and Risk of Metabolic Dysfunction-associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026 Apr;24(4):1195-1197. doi: 10.1016/j.cgh.2025.08.014. Epub 2025 Aug 25. PMID: 40865626; PMCID: PMC13134670.
- Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, Rudraraju M, Patil R, Behling C, Burch M, Chan DC, Tillman EJ, Zari A, de Temple B, Shringarpure R, Jain M, Rolph T, Cheng A, Yale K. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26;392(24):2413-2424. doi: 10.1056/NEJMoa2502242. Epub 2025 May 9. PMID: 40341827.
- Vuppalanchi R, Parvataneni S, Cihlar L, Longshore L, Orman E, Desai AP, Chalasani N. Inpatient Telehepatology at Community Hospitals: Expanding Access and Comanaging Complex Care. NEJM Catal Innov Care Deliv. 2025 Jun;6(6):10.1056/CAT.24.0412. doi: 10.1056/CAT.24.0412. Epub 2025 May 14. PMID: 41409718; PMCID: PMC12707029.
- Lammert C, Teal E, Ghabril M, Chalasani N. Incidence of Possible Drug-induced Liver Injury Due to Commonly Implicated Agents in the United States. Clin Gastroenterol Hepatol. 2025 May;23(6):1061-1062.e1. doi: 10.1016/j.cgh.2024.09.012. Epub 2024 Oct 22. PMID: 39447947.
- Le P, Tatar M, Rothberg MB, Wilson LA, Allende D, Diehl AM, Loomba R, Chalasani N, Neuschwander-Tetri BA, Kowdley K, Sanyal AJ, Tonascia J, Dasarathy S; NASH Clinical Research Network (CRN). Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2026 Jan 1;121(1):159-170. doi: 10.14309/ajg.0000000000003455. Epub 2025 Mar 31. PMID: 40163040; PMCID: PMC12584972.
- Ghabril M, Vuppalanchi R, Chalasani N. Drug-Induced Liver Injury in Patients With Chronic Liver Disease. Liver Int. 2025 Mar;45(3):e70019. doi: 10.1111/liv.70019. PMID: 39927421; PMCID: PMC11808633.
- Chalasani N, Hayashi PH, Luffer-Atlas D, Regev A, Watkins PB. Assessment of liver injury potential of investigational medicines in drug development. Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001281. Epub ahead of print. PMID: 39999469.
- Gopalakrishna H, Ghabril M, Gu J, Li YJ, Fontana RJ, Kleiner DE, Koh C, Chalasani N; Drug-Induced Liver Injury Network. Drug-induced Liver Injury Due to Medications for Alcohol Use Disorder: Results From the DILIN Prospective Study. J Addict Med. 2025 May-Jun 01;19(3):314-321. doi: 10.1097/ADM.0000000000001421. Epub 2024 Dec 9. PMID: 39651750; PMCID: PMC12133418.
- Chalasani N, Vilar-Gomez E, Loomba R, Yates KP, Diehl AM, Neuschwander-Tetri BA, Dasarathy S, Kowdley KV, Terrault N, Wilson LA, Tonascia J, Sanyal AJ. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024 Nov 1;80(5):1212-1226. doi: 10.1097/HEP.0000000000000896. Epub 2024 Apr 23. PMID: 38652636; PMCID: PMC11798878.
| Year | Degree | Institution |
|---|---|---|
| 1997 | Fellowship | Emory University School of Medicine |
| 1994 | Residency | Emory University School of Medicine |
| 1988 | MD | Kakatiya Medical College |
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Drug Hepatotoxicity
- Drug Metabolism
Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist.
Nephew LD; Wang Y; Mohamed K; Nichols D; Rawl SM; Orman E; Desai AP; Patidar KR; Ghabril M; Chalasani N; Kasting ML; Journal of viral hepatitis 2022 Mar 7
Nephew LD; Wang Y; Mohamed K; Nichols D; Rawl SM; Orman E; Desai AP; Patidar KR; Ghabril M; Chalasani N; Kasting ML; Journal of viral hepatitis 2022 Mar 7
Unexplained liver test elevations after SARS-CoV-2 vaccination.
Guardiola J; Lammert C; Teal E; Chalasani N; Journal of hepatology 2022 Mar 5
Guardiola J; Lammert C; Teal E; Chalasani N; Journal of hepatology 2022 Mar 5
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N; Hepatology (Baltimore, Md.) 2022 Mar 29
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N; Hepatology (Baltimore, Md.) 2022 Mar 29
Large Hepatic Adenomas and Hepatic Adenomatosis: A multicenter study of risk factors, interventions, and complications.
Lammert C; Toal E; Mathur K; Khungar V; House M; Roberts LR; Reddy KR; Chalasani N; The American journal of gastroenterology 2022 Mar 23
Lammert C; Toal E; Mathur K; Khungar V; House M; Roberts LR; Reddy KR; Chalasani N; The American journal of gastroenterology 2022 Mar 23
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
Brandman D; Boyle M; McPherson S; Van Natta ML; Sanyal AJ; Kowdley K; Neuschwander-Tetri B; Chalasani N; Abdelmalek MF; Terrault NA; McCullough A; Bettencourt R; Caussy C; Kleiner DE; Behling C; Tonascia J; Anstee QM; Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network.; Alimentary pharmacology & therapeutics 2022 Mar 17
Brandman D; Boyle M; McPherson S; Van Natta ML; Sanyal AJ; Kowdley K; Neuschwander-Tetri B; Chalasani N; Abdelmalek MF; Terrault NA; McCullough A; Bettencourt R; Caussy C; Kleiner DE; Behling C; Tonascia J; Anstee QM; Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network.; Alimentary pharmacology & therapeutics 2022 Mar 17
Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
Whitfield JB; Schwantes-An TH; Darlay R; Aithal GP; Atkinson SR; Bataller R; Botwin G; Chalasani NP; Cordell HJ; Daly AK; Day CP; Eyer F; Foroud T; Gleeson D; Goldman D; Haber PS; Jacquet JM; Liang T; Liangpunsakul S; Masson S; Mathurin P; Moirand R; McQuillin A; Moreno C; Morgan MY; Mueller S; Müllhaupt B; Nagy LE; Nahon P; Nalpas B; Naveau S; Perney P; Pirmohamed M; Seitz HK; Soyka M; Stickel F; Thompson A; Thursz MR; Trépo E; Morgan TR; Seth D; GenomALC Consortium.; Journal of hepatology 2022 Mar 11
Whitfield JB; Schwantes-An TH; Darlay R; Aithal GP; Atkinson SR; Bataller R; Botwin G; Chalasani NP; Cordell HJ; Daly AK; Day CP; Eyer F; Foroud T; Gleeson D; Goldman D; Haber PS; Jacquet JM; Liang T; Liangpunsakul S; Masson S; Mathurin P; Moirand R; McQuillin A; Moreno C; Morgan MY; Mueller S; Müllhaupt B; Nagy LE; Nahon P; Nalpas B; Naveau S; Perney P; Pirmohamed M; Seitz HK; Soyka M; Stickel F; Thompson A; Thursz MR; Trépo E; Morgan TR; Seth D; GenomALC Consortium.; Journal of hepatology 2022 Mar 11
Liver Transplantation in Recipients With Class III Obesity: Posttransplant Outcomes and Weight Gain.
Soma D; Park Y; Mihaylov P; Ekser B; Ghabril M; Lacerda M; Chalasani N; Mangus RS; Kubal CA; Transplantation direct 2022 Jan 5
Soma D; Park Y; Mihaylov P; Ekser B; Ghabril M; Lacerda M; Chalasani N; Mangus RS; Kubal CA; Transplantation direct 2022 Jan 5
Development of Alcohol-Associated Hepatitis Is Associated With Specific Changes in Gut-Modified Bile Acids.
Muthiah MD; Smirnova E; Puri P; Chalasani N; Shah VH; Kiani C; Taylor S; Mirshahi F; Sanyal AJ; Hepatology communications 2022 Jan 4
Muthiah MD; Smirnova E; Puri P; Chalasani N; Shah VH; Kiani C; Taylor S; Mirshahi F; Sanyal AJ; Hepatology communications 2022 Jan 4
Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
Devarbhavi H; Ghabril M; Barnhart H; Patil M; Raj S; Gu J; Chalasani N; Bonkovsky HL; Liver international : official journal of the International Association for the Study of the Liver 2022 Feb 7
Devarbhavi H; Ghabril M; Barnhart H; Patil M; Raj S; Gu J; Chalasani N; Bonkovsky HL; Liver international : official journal of the International Association for the Study of the Liver 2022 Feb 7
Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
Patidar KR; Naved MA; Grama A; Adibuzzaman M; Ali AA; Slaven JE; Desai AP; Ghabril MS; Nephew L; Chalasani N; Orman ES; Journal of hepatology 2022 Feb 22
Patidar KR; Naved MA; Grama A; Adibuzzaman M; Ali AA; Slaven JE; Desai AP; Ghabril MS; Nephew L; Chalasani N; Orman ES; Journal of hepatology 2022 Feb 22
Palliative Care, Patient-Reported Measures, and Outcomes in Hospitalized Patients With Cirrhosis.
Orman ES; Yousef A; Xu C; Shamseddeen H; Johnson AW; Nephew L; Ghabril M; Desai AP; Patidar KR; Chalasani N; Journal of pain and symptom management 2022 Feb 21
Orman ES; Yousef A; Xu C; Shamseddeen H; Johnson AW; Nephew L; Ghabril M; Desai AP; Patidar KR; Chalasani N; Journal of pain and symptom management 2022 Feb 21
Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey.
Huang R; Rao H; Lv F; Nan Y; Ren W; Huang Y; Li J; Tang H; Huang Y; Chalasani N; Wei L; Therapeutic innovation & regulatory science 2022 Feb 16
Huang R; Rao H; Lv F; Nan Y; Ren W; Huang Y; Li J; Tang H; Huang Y; Chalasani N; Wei L; Therapeutic innovation & regulatory science 2022 Feb 16
Neighborhood Poverty is Associated with Failure to be Waitlisted and Death During Liver Transplant Evaluation.
Mohamed KA; Ghabril M; Desai A; Orman E; Patidar KR; Holden J; Rawl S; Chalasani N; Kubal CS; Nephew L; Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2022 Apr 7
Mohamed KA; Ghabril M; Desai A; Orman E; Patidar KR; Holden J; Rawl S; Chalasani N; Kubal CS; Nephew L; Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2022 Apr 7
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ; NASH Clinical Research Network.; PloS one 2022 Apr 15
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ; NASH Clinical Research Network.; PloS one 2022 Apr 15
Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2021 Dec 25
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2021 Dec 25
In Memoriam-Lawrence Lumeng, MD: Researcher, Clinician, Leader, Mentor, Family Man, and Friend.
Chalasani NP; Crabb DW; Rex DK; Gastroenterology 2017 Sep 5
Chalasani NP; Crabb DW; Rex DK; Gastroenterology 2017 Sep 5
Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys.
Wattacheril J; Lavine JE; Chalasani NP; Guo X; Kwon S; Schwimmer J; Molleston JP; Loomba R; Brunt EM; Chen YI; Goodarzi MO; Taylor KD; Yates KP; Tonascia J; Rotter JI; The Journal of pediatrics 2017 Sep 14
Wattacheril J; Lavine JE; Chalasani NP; Guo X; Kwon S; Schwimmer J; Molleston JP; Loomba R; Brunt EM; Chen YI; Goodarzi MO; Taylor KD; Yates KP; Tonascia J; Rotter JI; The Journal of pediatrics 2017 Sep 14
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.
Puri P; Liangpunsakul S; Christensen JE; Shah VH; Kamath PS; Gores GJ; Walker S; Comerford M; Katz B; Borst A; Yu Q; Kumar DP; Mirshahi F; Radaeva S; Chalasani NP; Crabb DW; Sanyal AJ; TREAT Consortium.; Hepatology (Baltimore, Md.) 2017 Oct 30
Puri P; Liangpunsakul S; Christensen JE; Shah VH; Kamath PS; Gores GJ; Walker S; Comerford M; Katz B; Borst A; Yu Q; Kumar DP; Mirshahi F; Radaeva S; Chalasani NP; Crabb DW; Sanyal AJ; TREAT Consortium.; Hepatology (Baltimore, Md.) 2017 Oct 30
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K; Hepatology (Baltimore, Md.) 2017 Dec 9
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K; Hepatology (Baltimore, Md.) 2017 Dec 9
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K; Hepatology (Baltimore, Md.) 2017 Dec 9
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K; Hepatology (Baltimore, Md.) 2017 Dec 9
An exploratory genome-wide analysis of genetic risk for alcoholic hepatitis.
Beaudoin JJ; Long N; Liangpunsakul S; Puri P; Kamath PS; Shah V; Sanyal AJ; Crabb DW; Chalasani NP; Urban TJ; TREAT Consortium.; Scandinavian journal of gastroenterology 2017 Aug 4
Beaudoin JJ; Long N; Liangpunsakul S; Puri P; Kamath PS; Shah V; Sanyal AJ; Crabb DW; Chalasani NP; Urban TJ; TREAT Consortium.; Scandinavian journal of gastroenterology 2017 Aug 4
Death and liver transplantation within 2 years of onset of drug-induced liver injury.
Hayashi PH; Rockey DC; Fontana RJ; Tillmann HL; Kaplowitz N; Barnhart HX; Gu J; Chalasani NP; Reddy KR; Sherker AH; Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN) Investigators.; Hepatology (Baltimore, Md.) 2017 Aug 26
Hayashi PH; Rockey DC; Fontana RJ; Tillmann HL; Kaplowitz N; Barnhart HX; Gu J; Chalasani NP; Reddy KR; Sherker AH; Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN) Investigators.; Hepatology (Baltimore, Md.) 2017 Aug 26
Differential Expression of miRNAs in Nontumor Liver Tissue of Patients With Hepatocellular Cancer Caused by Nonalcoholic Steatohepatitis Cirrhosis.
Liang T; Chalasani NP; Williams KE; Sarasani V; Janga SC; Vuppalanchi R; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Oct 22
Liang T; Chalasani NP; Williams KE; Sarasani V; Janga SC; Vuppalanchi R; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Oct 22
Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat.
Vuppalanchi R; Chalasani N; Digestive diseases and sciences 2016 Mar 24
Vuppalanchi R; Chalasani N; Digestive diseases and sciences 2016 Mar 24
Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients.
Ghabril M; Agarwal S; Lacerda M; Chalasani N; Kwo P; Tector AJ; Transplantation 2016 Jan
Ghabril M; Agarwal S; Lacerda M; Chalasani N; Kwo P; Tector AJ; Transplantation 2016 Jan
Febuxostat-induced acute liver injury.
Bohm M; Vuppalanchi R; Chalasani N; Drug-Induced Liver Injury Network (DILIN); Hepatology (Baltimore, Md.) 2016 Feb 3
Bohm M; Vuppalanchi R; Chalasani N; Drug-Induced Liver Injury Network (DILIN); Hepatology (Baltimore, Md.) 2016 Feb 3
Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes.
Wong VW; Chalasani N; Journal of hepatology 2016 Feb 26
Wong VW; Chalasani N; Journal of hepatology 2016 Feb 26
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
Crabb DW; Bataller R; Chalasani NP; Kamath PS; Lucey M; Mathurin P; McClain C; McCullough A; Mitchell MC; Morgan TR; Nagy L; Radaeva S; Sanyal A; Shah V; Szabo G; NIAAA Alcoholic Hepatitis Consortia; Gastroenterology 2016 Feb 24
Crabb DW; Bataller R; Chalasani NP; Kamath PS; Lucey M; Mathurin P; McClain C; McCullough A; Mitchell MC; Morgan TR; Nagy L; Radaeva S; Sanyal A; Shah V; Szabo G; NIAAA Alcoholic Hepatitis Consortia; Gastroenterology 2016 Feb 24
Perilipin Staining Distinguishes Between Steatosis and Nonalcoholic Steatohepatitis in Adults and Children.
Carr RM; Dhir R; Mahadev K; Comerford M; Chalasani NP; Ahima RS; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Aug 25
Carr RM; Dhir R; Mahadev K; Comerford M; Chalasani NP; Ahima RS; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Aug 25
Poor Performance Status is Associated with Increased Mortality in Patients with Cirrhosis.
Orman ES; Ghabril M; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Apr 1
Orman ES; Ghabril M; Chalasani N; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016 Apr 1
Nonalcoholic Fatty Liver Disease in Latinos.
Saab S; Manne V; Nieto J; Schwimmer JB; Chalasani NP; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015 May 11
Saab S; Manne V; Nieto J; Schwimmer JB; Chalasani NP; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015 May 11
A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.
Eaton JE; Juran BD; Atkinson EJ; Schlicht EM; Xie X; de Andrade M; Lammert CS; Luketic VA; Odin JA; Koteish AA; Kowdley KV; Chopra KB; Hirschfield GM; Chalasani NP; Lazaridis KN; Alimentary pharmacology & therapeutics 2015 Mar 17
Eaton JE; Juran BD; Atkinson EJ; Schlicht EM; Xie X; de Andrade M; Lammert CS; Luketic VA; Odin JA; Koteish AA; Kowdley KV; Chopra KB; Hirschfield GM; Chalasani NP; Lazaridis KN; Alimentary pharmacology & therapeutics 2015 Mar 17
Response to levy.
Navarro V; Chalasani NP; The American journal of gastroenterology 2015 Mar
Navarro V; Chalasani NP; The American journal of gastroenterology 2015 Mar
Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
Hayashi PH; Fontana RJ; Chalasani NP; Stolz AA; Talwalker JA; Navarro VJ; Lee WM; Davern TJ; Kleiner DE; Gu J; Hoofnagle JH; U.S. DILIN Investigators; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015 Feb 24
Hayashi PH; Fontana RJ; Chalasani NP; Stolz AA; Talwalker JA; Navarro VJ; Lee WM; Davern TJ; Kleiner DE; Gu J; Hoofnagle JH; U.S. DILIN Investigators; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015 Feb 24
Obesity associated molecular forms of C-reactive protein in human.
Asztalos BF; Horan MS; Horvath KV; McDermott AY; Chalasani NP; Schaefer EJ; PloS one 2014 Oct 9
Asztalos BF; Horan MS; Horvath KV; McDermott AY; Chalasani NP; Schaefer EJ; PloS one 2014 Oct 9
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.
Chalasani NP; Hayashi PH; Bonkovsky HL; Navarro VJ; Lee WM; Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology; The American journal of gastroenterology 2014 Jun 17
Chalasani NP; Hayashi PH; Bonkovsky HL; Navarro VJ; Lee WM; Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology; The American journal of gastroenterology 2014 Jun 17
Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
Force J; Saxena R; Schneider BP; Storniolo AM; Sledge GW Jr; Chalasani N; Vuppalanchi R; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Apr 28
Force J; Saxena R; Schneider BP; Storniolo AM; Sledge GW Jr; Chalasani N; Vuppalanchi R; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Apr 28
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy.
Yang CY; Ma X; Tsuneyama K; Huang S; Takahashi T; Chalasani NP; Bowlus CL; Yang GX; Leung PS; Ansari AA; Wu L; Coppel RL; Gershwin ME; Hepatology (Baltimore, Md.) 2014 Apr 1
Yang CY; Ma X; Tsuneyama K; Huang S; Takahashi T; Chalasani NP; Bowlus CL; Yang GX; Leung PS; Ansari AA; Wu L; Coppel RL; Gershwin ME; Hepatology (Baltimore, Md.) 2014 Apr 1
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
Kleiner DE; Chalasani NP; Lee WM; Fontana RJ; Bonkovsky HL; Watkins PB; Hayashi PH; Davern TJ; Navarro V; Reddy R; Talwalkar JA; Stolz A; Gu J; Barnhart H; Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN); Hepatology (Baltimore, Md.) 2013 Dec 18
Kleiner DE; Chalasani NP; Lee WM; Fontana RJ; Bonkovsky HL; Watkins PB; Hayashi PH; Davern TJ; Navarro V; Reddy R; Talwalkar JA; Stolz A; Gu J; Barnhart H; Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN); Hepatology (Baltimore, Md.) 2013 Dec 18
Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided?
Hayashi PH; Chalasani NP; CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2012 Aug 13
Hayashi PH; Chalasani NP; CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2012 Aug 13
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J; NASH CRN Research Group; Contemporary clinical trials 2008 Sep 10
Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J; NASH CRN Research Group; Contemporary clinical trials 2008 Sep 10
Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report.
Malireddy SR; Pinto AG; Chalasani NP; Gorski JC; Hall SD; Transplantation proceedings 2008 Jun
Malireddy SR; Pinto AG; Chalasani NP; Gorski JC; Hall SD; Transplantation proceedings 2008 Jun
Insulin resistance, hepatitis C, and liver transplantation.
Alsatie M; Pandya P; Chalasani NP; Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2008 Feb
Alsatie M; Pandya P; Chalasani NP; Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2008 Feb
Complete reversal of glycogen hepatopathy with pancreas transplantation: two cases.
Fridell JA; Saxena R; Chalasani NP; Goggins WC; Powelson JA; Cummings OW; Transplantation 2007 Jan 15
Fridell JA; Saxena R; Chalasani NP; Goggins WC; Powelson JA; Cummings OW; Transplantation 2007 Jan 15
Metabolic syndrome following liver transplantation is associated with major vascular events.
Liangpunsakul S; Chalasani NP; Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007 Aug
Liangpunsakul S; Chalasani NP; Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007 Aug
Autoimmune hepatitis triggered by statins.
Alla V; Abraham J; Siddiqui J; Raina D; Wu GY; Chalasani NP; Bonkovsky HL; Journal of clinical gastroenterology 2006 Sep
Alla V; Abraham J; Siddiqui J; Raina D; Wu GY; Chalasani NP; Bonkovsky HL; Journal of clinical gastroenterology 2006 Sep
Severe liver injury after initiating therapy with atomoxetine in two children.
Lim JR; Faught PR; Chalasani NP; Molleston JP; The Journal of pediatrics 2006 Jun
Lim JR; Faught PR; Chalasani NP; Molleston JP; The Journal of pediatrics 2006 Jun
Abnormal enhancing lesion of dentate nuclei causing neurologic symptoms induced by metronidazole toxicity.
Deenadayalu VP; Orinion EJ; Chalasani NP; Yoo HY; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005 Mar
Deenadayalu VP; Orinion EJ; Chalasani NP; Yoo HY; Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005 Mar
Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks.
Chalasani NP; Valdecanas MA; Gopal AK; McGowan JE Jr; Jurado RL; Chest 1995 Oct
Chalasani NP; Valdecanas MA; Gopal AK; McGowan JE Jr; Jurado RL; Chest 1995 Oct
Alpha Omega Alpha Honor Medical Society
American Association of Physicians
American Association of Study of Liver Disease, Fellow (FAASLD)
American College of Gastroenterology, Fellow (FACG)
American College of Physicians
American Gastroenterology Association, Fellow (AGAF)
Transplant Hepatology
Gastroenterology
Internal Medicine
- Acute and chronic liver disease
- Metabolic dysfunction-Associated Steatohepatitis (MASH)
- Drug Hepatotoxicity
- Drug Metabolism
Org: American Association of Physicians
Desc: Member, AAP
Scope: National
Date:
Desc: Member, AAP
Scope: National
Date:
Org: American Society of Clinical Investigation
Desc: Member, ASCI
Scope: National
Date:
Desc: Member, ASCI
Scope: National
Date:
Org: Alpha Omega Alpha
Desc: Member, AOA
Scope: National
Date:
Desc: Member, AOA
Scope: National
Date:
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.